D. Boral Capital Reaffirms “Buy” Rating for Estrella Immunopharma (NASDAQ:ESLA)

Estrella Immunopharma (NASDAQ:ESLA)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a research report issued on Monday,Benzinga reports. They presently have a $8.00 price target on the stock. D. Boral Capital’s target price indicates a potential upside of 451.72% from the company’s current price.

ESLA has been the topic of a number of other reports. Wall Street Zen raised shares of Estrella Immunopharma from a “sell” rating to a “hold” rating in a research note on Saturday, January 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Estrella Immunopharma in a report on Wednesday, January 28th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Estrella Immunopharma currently has a consensus rating of “Hold” and an average target price of $8.00.

Estrella Immunopharma Trading Up 9.8%

Shares of ESLA stock opened at $1.45 on Monday. Estrella Immunopharma has a 1-year low of $0.73 and a 1-year high of $3.15. The stock has a market cap of $54.77 million, a price-to-earnings ratio of -4.26 and a beta of 0.55. The stock has a 50-day moving average of $1.41 and a 200-day moving average of $1.44.

Estrella Immunopharma (NASDAQ:ESLA) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.06.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.